Alan H. Bryce, MD

Alan H. Bryce, MD

City of Hope

Phoenix, Arizona

Alan H. Bryce, MD, is a medical oncologist and chief clinical officer at City of Hope in Phoenix, Arizona. Dr. Bryce holds an appointment as a professor with the Department of Medical Oncology & Therapeutics Research, with City of Hope, as well as an appointment as a professor of Molecular Medicine at Translational Genomics Research Institute (TGen), which is also part of City of Hope.

Prior to joining City of Hope, Dr. Bryce spent 12 years at the Mayo Clinic in Phoenix, where he served as chair of the Division of Hematology and Medical Oncology, as well as Director of the Mayo Clinic Arizona Comprehensive Cancer Center. Dr. Bryce received his medical degree from the Chicago Medical School, and then completed an internal medicine residency and a hematology and oncology fellowship at the Mayo Clinic in Rochester, Minnesota. During his time at Mayo, Dr. Bryce served as an international co-principal investigator on multiple clinical trials for prostate cancer, with his research focused on cancer genetics, novel therapies and immunotherapeutic approaches.

Talks by Alan H. Bryce, MD

Putting Germline Testing into Context: A Primer and Current Knowledge

Putting Germline Testing into Context: A Primer and Current Knowledge

Posted by | Oct 2024

Alan H. Bryce, MD, explores the critical role of germline testing in prostate cancer, providing a primer on its current applications. He emphasizes identifying these genetic markers for patient management and familial risk assessment.

The 9-minute presentation considers the most relevant genes associated with prostate cancer risk, including BRCA1, BRCA2, and ATM. Dr. Bryce also highlights data problems with germline variants, questioning the representation of diverse racial and ethnic groups in clinical trials.

Read More
Putting Germline Testing into Context – A Primer and Current Knowledge

Putting Germline Testing into Context – A Primer and Current Knowledge

Posted by | Jul 2024

Alan H. Bryce, MD, outlines the current state and potential future directions of germline testing in prostate cancer detection and treatment. He begins with a review of the currently known genetic mutations associated with prostate cancer.

Dr. Bryce then reviews the NCCN criteria for germline genetic testing for patients with new or previously diagnosed prostate cancer. He presents data that supports the idea that current testing guidelines are not effective in identifying the presence of known pathogenic germline variants (PVGs) in patients with prostate cancer.

Dr. Bryce then examines the relationship between disease progression and the presence of PVGs. He presents data illustrating the correlation of certain PVGs and the likelihood of disease progression.

Dr. Bryce concludes by highlighting the lack of available data for different racial groups. He notes that most of the available PGV data is based on the testing and surveillance of Caucasian males, leaving all other racial groups underrepresented in the data.

Read More

Join the GRU Community

- Why Join? -